|
US20120121515A1
(en)
|
2009-03-13 |
2012-05-17 |
Lenny Dang |
Methods and compositions for cell-proliferation-related disorders
|
|
CA2758071C
(en)
|
2009-04-06 |
2018-01-09 |
Agios Pharmaceuticals, Inc. |
Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
|
|
TWI598337B
(zh)
|
2009-06-29 |
2017-09-11 |
阿吉歐斯製藥公司 |
治療化合物及組成物
|
|
ES2618630T3
(es)
|
2009-06-29 |
2017-06-21 |
Agios Pharmaceuticals, Inc. |
Composiciones terapéuticas y métodos de uso relacionados
|
|
WO2011050210A1
(en)
|
2009-10-21 |
2011-04-28 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
|
EP2525790B1
(en)
|
2009-10-21 |
2020-05-27 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
|
WO2012083246A1
(en)
|
2010-12-17 |
2012-06-21 |
Agios Pharmaceuticals, Inc. |
Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
|
|
ES2569712T3
(es)
|
2010-12-21 |
2016-05-12 |
Agios Pharmaceuticals, Inc. |
Activadores de PKM2 bicíclicos
|
|
TWI549947B
(zh)
|
2010-12-29 |
2016-09-21 |
阿吉歐斯製藥公司 |
治療化合物及組成物
|
|
SMT202400081T1
(it)
|
2011-05-03 |
2024-03-13 |
Agios Pharmaceuticals Inc |
Attivatori della piruvato chinasi per uso in terapia
|
|
CN102827170A
(zh)
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
CN102827073A
(zh)
*
|
2011-06-17 |
2012-12-19 |
安吉奥斯医药品有限公司 |
治疗活性组合物和它们的使用方法
|
|
BR112014007310A2
(pt)
*
|
2011-09-27 |
2017-04-04 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
|
|
PE20142098A1
(es)
|
2012-01-06 |
2015-01-08 |
Agios Pharmaceuticals Inc |
Compuestos terapeuticamente activos y sus metodos de uso
|
|
US9474779B2
(en)
|
2012-01-19 |
2016-10-25 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compositions and their methods of use
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
EP2906212A4
(en)
|
2012-10-15 |
2016-06-08 |
Agios Pharmaceuticals Inc |
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
JP6387360B2
(ja)
|
2013-03-14 |
2018-09-05 |
ノバルティス アーゲー |
変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
|
|
EP3004396B1
(en)
|
2013-06-06 |
2019-10-16 |
The General Hospital Corporation |
Compositions for the treatment of cancer
|
|
WO2015003355A2
(en)
*
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
AU2014287122B9
(en)
|
2013-07-11 |
2018-11-01 |
Les Laboratoires Servier |
N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as IDH2 mutants inhibitors for the treatment of cancer
|
|
CN105593215B
(zh)
|
2013-07-11 |
2019-01-15 |
安吉奥斯医药品有限公司 |
用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
|
|
WO2015003360A2
(en)
*
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
WO2015010297A1
(en)
|
2013-07-25 |
2015-01-29 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
SI3077395T1
(en)
*
|
2013-12-05 |
2018-03-30 |
Pfizer Inc. |
Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides
|
|
EA031655B1
(ru)
|
2014-02-11 |
2019-02-28 |
Байер Фарма Акциенгезельшафт |
Бензимидазол-2-амины в качестве ингибиторов midhi
|
|
US9951027B2
(en)
|
2014-02-11 |
2018-04-24 |
Bayer Pharma Aktiengesellschaft |
Benzimidazol-2-amines as MIDH1 inhibitors
|
|
NZ723859A
(en)
|
2014-03-14 |
2023-01-27 |
Servier Lab |
Pharmaceutical compositions of therapeutically active compounds and their uses
|
|
WO2015169130A1
(zh)
*
|
2014-05-09 |
2015-11-12 |
上海科胜药物研发有限公司 |
新的沃替西汀中间体及其合成方法
|
|
AU2015317327B9
(en)
*
|
2014-09-19 |
2020-04-09 |
Forma Therapeutics, Inc. |
Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
|
|
EP3194383B1
(en)
|
2014-09-19 |
2019-11-06 |
Forma Therapeutics, Inc. |
Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
|
|
MA53352A
(fr)
|
2014-09-19 |
2021-09-15 |
Forma Therapeutics Inc |
Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase
|
|
MX372964B
(es)
*
|
2014-09-19 |
2020-03-27 |
Forma Therapeutics Inc |
Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
|
|
AU2015369712B2
(en)
|
2014-12-22 |
2020-05-07 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Mutant IDH1 inhibitors useful for treating cancer
|
|
US10407419B2
(en)
|
2015-04-21 |
2019-09-10 |
Forma Therapeutics, Inc. |
Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
|
|
US9624175B2
(en)
|
2015-04-21 |
2017-04-18 |
Forma Therapeutics, Inc. |
Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
|
|
CA2989111C
(en)
|
2015-06-11 |
2023-10-03 |
Agios Pharmaceuticals, Inc. |
Methods of using pyruvate kinase activators
|
|
WO2017035057A1
(en)
*
|
2015-08-24 |
2017-03-02 |
The Methodist Hospital |
Compositions and methods for treating ewing family tumors
|
|
KR102699521B1
(ko)
|
2015-10-15 |
2024-08-26 |
르 라보레또레 쎄르비에르 |
악성 종양의 치료를 위한 조합물 요법
|
|
FI3362065T3
(fi)
|
2015-10-15 |
2024-06-19 |
Servier Lab |
Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi
|
|
JP6961879B2
(ja)
*
|
2015-12-30 |
2021-11-05 |
レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ |
変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
|
|
WO2017153952A1
(en)
*
|
2016-03-10 |
2017-09-14 |
Glaxosmithkline Intellectual Property Development Limited |
5-sulfamoyl-2-hydroxybenzamide derivatives
|
|
TW201736341A
(zh)
*
|
2016-03-22 |
2017-10-16 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
丙啶磺醯胺類化合物及其使用方法
|
|
HRP20211462T1
(hr)
|
2017-04-24 |
2021-12-24 |
Aurigene Discovery Technologies Limited |
Postupci uporabe za trisupstituirane derivate benzotriazola kao inhibitora dihidroorotatne oksigenaze
|
|
US20180369206A1
(en)
|
2017-04-24 |
2018-12-27 |
Aurigene Discovery Technologies Limited |
Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
|
|
CN109897044A
(zh)
|
2017-12-07 |
2019-06-18 |
北京大学 |
抗神经病理性疼痛化合物及其制备方法
|
|
TWI818954B
(zh)
|
2018-02-20 |
2023-10-21 |
法商施維雅藥廠 |
三取代之苯并三唑衍生物的使用方法
|
|
US11013733B2
(en)
|
2018-05-16 |
2021-05-25 |
Forma Therapeutics, Inc. |
Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
|
|
US20210196701A1
(en)
|
2018-05-16 |
2021-07-01 |
Forma Therapeutics, Inc. |
Inhibiting mutant idh-1
|
|
WO2019222551A1
(en)
|
2018-05-16 |
2019-11-21 |
Forma Therapeutics, Inc. |
Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
|
|
US11311527B2
(en)
|
2018-05-16 |
2022-04-26 |
Forma Therapeutics, Inc. |
Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
|
|
US11013734B2
(en)
|
2018-05-16 |
2021-05-25 |
Forma Therapeutics, Inc. |
Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
|
|
CN108822082B
(zh)
*
|
2018-06-06 |
2020-11-03 |
青岛科技大学 |
一种含氟吡啶哌嗪酰胺类化合物及其应用
|
|
US10980788B2
(en)
|
2018-06-08 |
2021-04-20 |
Agios Pharmaceuticals, Inc. |
Therapy for treating malignancies
|
|
CN116768806B
(zh)
*
|
2022-03-11 |
2026-01-02 |
中国农业大学 |
取代的1,2,3-三唑类化合物及其制备方法和在防治植物病害中的用途
|
|
CN114685399A
(zh)
*
|
2022-04-26 |
2022-07-01 |
河北广祥制药有限公司 |
一种乌拉地尔中间体1-(2-甲氧基苯基)哌嗪及其盐的制备方法
|
|
CN116425653A
(zh)
*
|
2023-03-22 |
2023-07-14 |
烟台盛凯伦化学科技有限公司 |
一种n,n’-二(对乙氧基苯基)-1,4-苯二甲亚胺的制备方法
|
|
EP4712963A2
(en)
*
|
2023-05-18 |
2026-03-25 |
Concarlo Therapeutics, Inc. |
Small molecule inhibitors of p27
|